معرفی
Jozef Rozenski is a Professor at KU Leuven within the Faculty of Pharmaceutical Sciences, Department of Pharmaceutical and Pharmacological Sciences. He leads research in the Laboratory for Medicinal Chemistry (Rega Institute) and serves on multiple institutional councils including the Sustainability Council and Faculty Council.
His research focuses on mass spectrometry applications for nucleic acid analysis, drug metabolism, and organic compound structure elucidation. Key areas include RNA posttranscriptional modifications, LC/MS techniques, ion mobility spectrometry, and electrochemistry-mass spectrometry coupling. His work bridges analytical chemistry with pharmaceutical development.
Rozenski's recent publications demonstrate expertise in antibacterial compound development (particularly paFabV inhibitors targeting Pseudomonas), antiviral NNRTIs, CCR5 signaling inhibitors, and coronavirus replication mechanisms. His research consistently applies advanced mass spectrometry to solve complex pharmaceutical problems.
He serves as promotor and co-promotor on major research projects including 'Development of XNA ligases for synthetic biology' (2015-2025) and 'Directed evolution of bioactive compounds' (2019-2025), securing significant institutional funding. His teaching portfolio includes Analytical Tools for Drug Development, Mass Spectrometry, and Laboratory Automation courses.
Rozenski actively participates in professional societies including the Belgian and American Societies for Mass Spectrometry, maintaining strong industry-academic collaborations through his laboratory's focus on drug development technologies.